3BNC117

DRUG9 trials

Sponsors

Rockefeller University, Aarhus University Hospital, Frontier Biotechnologies Inc.

Conditions

HIV-1 InfectionHIV-1-infectionHIV/AIDSHivHuman Immunodeficiency VirusHuman Immunodeficiency Virus (HIV)

Phase 1

3BNC117 and 10-1074 in HIV Uninfected Adults

CompletedNCT02824536

Rockefeller UniversityHuman Immunodeficiency Virus

Start: 2016-06-23End: 2018-01-09Updated: 2018-04-17

3BNC117 and 10-1074 in HIV-infected Individuals

CompletedNCT02825797

Rockefeller UniversityHuman Immunodeficiency Virus (HIV)

Start: 2016-06-30End: 2018-08-15Updated: 2018-08-21

3BNC117 and 10-1074 in ART-treated Individuals

CompletedNCT03526848

Rockefeller UniversityHuman Immunodeficiency Virus

Start: 2018-06-05End: 2022-02-11Updated: 2025-10-01

Phase 2

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

CompletedNCT02446847

Rockefeller UniversityHIV-1 Infection

Start: 2015-03-11End: 2017-03-25Updated: 2020-07-23

A Study of the Safety and Antiretroviral Activity of 3BNC117

CompletedNCT02588586

Rockefeller UniversityHIV-1 Infection

Start: 2015-10-31End: 2018-04-30Updated: 2021-06-16

Romidepsin Plus 3BNC117 Phase 2a Study

CompletedNCT02850016

Rockefeller UniversityHuman Immunodeficiency Virus (HIV)

Start: 2017-01-06End: 2020-12-31Updated: 2022-07-14

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

CompletedNCT03041012

Aarhus University HospitalHiv

Start: 2017-01-20End: 2022-12-30Updated: 2025-04-18

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Frontier Biotechnologies Inc.HIV-1-infection

Start: 2018-12-17End: 2022-12-31Target: 80Updated: 2021-09-29

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Frontier Biotechnologies Inc.HIV/AIDS

Start: 2021-05-01End: 2022-12-01Target: 24Updated: 2021-03-26

Related Papers

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.

2022-10-17102 citations

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.

2022-01-2460 citations

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

2019-08-0871 citations

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

2018-09-26219 citations